Skip to main content
. 2019 Aug 8;18(4):2369–2377. doi: 10.3892/etm.2019.7869

Figure 1.

Figure 1.

PI3K/Akt/mTOR pathway mutation in thyroid cancers. (A) PI3K/AKT/mTOR pathway (includes PIK3CA, PTEN, PIK3C2G, PIK3CG, PIK3C3, PIK3R1, PIK3R2, AKT3, TSC1, TSC2 and MTOR) mutation in well-differentiated thyroid tumor types (PTC) and those with poor differentiation (PDTC and ATC). (B) Kaplan-Meier survival analysis of 84PDTC and 33 ATC with log-rank P-values indicating significantly shorter survival in mutation cases (P=0.044). (C) Overall median survival of 117 PDTC and ATC cases. ATC, anaplastic thyroid cancer; Cum, cumulative; wild, wild-type; PTEN, phosphatase and tensin homolog; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α; TCGA, The Cancer Genome Atlas; MSKCC, Memorial Sloan Kettering Cancer Center; PTC, papillary thyroid carcinoma; PDTC, poorly differentiated thyroid tumor; TSC1, TSC subunit 1.